Subscribe To
Zevra's rare find: unearthing value in niche rare diseases the market overlooks
Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns w...
September 5, 2023, 1:30 am
Acer therapeutics reports q1 2023 financial results and provides corporate update
U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE...
May 15, 2023, 9:10 pm
Acer therapeutics and relief therapeutics announce u.s. fda approval of olpruva™ for patients with urea cycle disorders
New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn...
December 27, 2022, 1:30 pm